Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Revolution Medicines (RVMDW) EBT (2019 - 2025)

Historic EBT for Revolution Medicines (RVMDW) over the last 7 years, with Q3 2025 value amounting to -$305.2 million.

  • Revolution Medicines' EBT fell 9528.43% to -$305.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$961.7 million, marking a year-over-year decrease of 6970.19%. This contributed to the annual value of -$600.8 million for FY2024, which is 3658.97% down from last year.
  • Per Revolution Medicines' latest filing, its EBT stood at -$305.2 million for Q3 2025, which was down 9528.43% from -$247.8 million recorded in Q2 2025.
  • Revolution Medicines' EBT's 5-year high stood at -$37.2 million during Q1 2021, with a 5-year trough of -$305.2 million in Q3 2025.
  • Moreover, its 5-year median value for EBT was -$98.3 million (2023), whereas its average is -$118.1 million.
  • As far as peak fluctuations go, Revolution Medicines' EBT crashed by 750.63% in 2022, and later plummeted by 18464.42% in 2023.
  • Quarter analysis of 5 years shows Revolution Medicines' EBT stood at -$52.7 million in 2021, then fell by 7.51% to -$56.6 million in 2022, then tumbled by 184.64% to -$161.2 million in 2023, then decreased by 21.17% to -$195.3 million in 2024, then tumbled by 56.26% to -$305.2 million in 2025.
  • Its last three reported values are -$305.2 million in Q3 2025, -$247.8 million for Q2 2025, and -$213.4 million during Q1 2025.